Genvio Pharma Ltd.
Crizotinib Cancer (oncology)
Originator: Xalkori · Pfizer
| Brand | Strength | Form | Unit price | ≈ USD | Pack |
|---|---|---|---|---|---|
| Algrofin | 250 mg capsule | — | — | — | — |
| Algrofin | 250 mg | Capsule | BDT 750 | US$6.10 | 7 x 4: ৳ 21,000.00 |
Ibrutinib Cancer (oncology)
Originator: Imbruvica · Pharmacyclics LLC (an AbbVie company) and Janssen Biotech, Inc. (Johnson & Johnson) - developed and commercialised jointly; US distributor of record: Pharmacyclics LLC
| Brand | Strength | Form | Unit price | ≈ USD | Pack |
|---|---|---|---|---|---|
| Notafol | 140 mg capsule | — | — | — | — |
| Notafol | 140 mg | Capsule | BDT 750 | US$6.10 | 9 x 10: ৳ 67,500.00 |
Olaparib Cancer (oncology)
Originator: Lynparza · AstraZeneca (distributed by AstraZeneca Pharmaceuticals LP); developed and commercialised in collaboration with Merck (MSD outside the US and Canada)
| Brand | Strength | Form | Unit price | ≈ USD | Pack |
|---|---|---|---|---|---|
| Inpoza | 150 mg | Tablet | BDT 1,000 | US$8.14 | 6 x 10: ৳ 60,000.00 |
Osimertinib Cancer (oncology)
Originator: Tagrisso · AstraZeneca
| Brand | Strength | Form | Unit price | ≈ USD | Pack |
|---|---|---|---|---|---|
| Irmukin | 80 mg tablet | — | — | — | — |
| Irmukin | 80 mg | Tablet | BDT 425 | US$3.46 | 3 x 10: ৳ 12,750.00 |
Palbociclib Cancer (oncology)
Originator: Ibrance · Pfizer Inc. (Pfizer Laboratories Div Pfizer Inc)
| Brand | Strength | Form | Unit price | ≈ USD | Pack |
|---|---|---|---|---|---|
| Cykin | 125 mg | Capsule | BDT 400 | US$3.26 | 7 x 4: ৳ 11,200.00 |
This page is an information resource for healthcare professionals, licensed importers and patients under medical care. It is not medical advice, not a prescription service, and not an offer to sell prescription medicines to the public.
Need a verified quotation?
Send us the molecule, strength, pack size, quantity and destination country. We reply with a batch-traceable quotation, certificates of analysis and shipping documentation.
We supply licensed pharmacies, hospitals, importers and distributors — not direct-to-consumer patients.